EP2501372A4 - Infusion intraveineuse de curcumine et de bloqueur des canaux calciques - Google Patents

Infusion intraveineuse de curcumine et de bloqueur des canaux calciques

Info

Publication number
EP2501372A4
EP2501372A4 EP20100832224 EP10832224A EP2501372A4 EP 2501372 A4 EP2501372 A4 EP 2501372A4 EP 20100832224 EP20100832224 EP 20100832224 EP 10832224 A EP10832224 A EP 10832224A EP 2501372 A4 EP2501372 A4 EP 2501372A4
Authority
EP
European Patent Office
Prior art keywords
curcumin
calcium channel
intravenous infusion
channel blocker
blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP20100832224
Other languages
German (de)
English (en)
Other versions
EP2501372A2 (fr
Inventor
Lawrence Helson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of EP2501372A2 publication Critical patent/EP2501372A2/fr
Publication of EP2501372A4 publication Critical patent/EP2501372A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP20100832224 2009-11-19 2010-11-19 Infusion intraveineuse de curcumine et de bloqueur des canaux calciques Ceased EP2501372A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26274509P 2009-11-19 2009-11-19
PCT/US2010/057332 WO2011063178A2 (fr) 2009-11-19 2010-11-19 Infusion intraveineuse de curcumine et de bloqueur des canaux calciques
US12/949,897 US8747890B2 (en) 2009-11-19 2010-11-19 Intravenous infusion of curcumin and a calcium channel blocker

Publications (2)

Publication Number Publication Date
EP2501372A2 EP2501372A2 (fr) 2012-09-26
EP2501372A4 true EP2501372A4 (fr) 2013-04-10

Family

ID=44011450

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20100832224 Ceased EP2501372A4 (fr) 2009-11-19 2010-11-19 Infusion intraveineuse de curcumine et de bloqueur des canaux calciques

Country Status (3)

Country Link
US (2) US8747890B2 (fr)
EP (1) EP2501372A4 (fr)
WO (1) WO2011063178A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393198B2 (en) * 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
GB2507884B (en) 2011-06-03 2019-10-23 Signpath Pharma Inc Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US9138411B2 (en) 2012-08-31 2015-09-22 University Of North Texas Health Science Center At Fort Worth Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy
CA2933204C (fr) 2013-12-18 2020-04-28 Signpath Pharma, Inc. Attenuation liposomale de l'inhibition induite par medicament du canal ikr cardiaque
EP3151837B1 (fr) 2014-06-03 2023-03-15 Signpath Pharma, Inc. Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des médicaments provoquant des canalopathies
WO2016128358A1 (fr) * 2015-02-09 2016-08-18 Biocrine Ab Méthodes pour traiter le diabète et/ou limiter son développement chez les patients atteints de sclérose latérale amyotrophique
KR102181659B1 (ko) 2016-04-27 2020-11-24 사인패스 파마 인코포레이티드 약물 유발된 방실 차단의 방지
JPWO2018088566A1 (ja) * 2016-11-14 2019-10-10 学校法人慶應義塾 虚血性疾患、緑内障、視神経疾患、網膜変性疾患、血管新生性網膜疾患、がん、神経変性、もしくは自己免疫疾患の治療又は予防剤、及び低酸素誘導因子阻害剤
IT201600126405A1 (it) * 2016-12-14 2018-06-14 Raffaella Bertoglio Composizione farmaceutica per la prevenzione e il trattamento della degenerazione maculare senile
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070949A1 (fr) * 1999-05-20 2000-11-30 Heng Madalene C Y Methode d'utilisation de curcumin soluble pour inhiber une phosphorylase kinase dans des maladies inflammatoires

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
CA2536738A1 (fr) * 2003-08-26 2005-03-10 Research Development Foundation Administration par aerosol de curcumine
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
US20090143433A1 (en) * 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
ITMI20042353A1 (it) 2004-12-10 2005-03-10 Uni Degli Studi Di Modena E Re Peptidi per la veicolazione di farmaci
US7507864B2 (en) * 2006-08-01 2009-03-24 Salisbury University Method for the synthesis of curcumin analogues
US20080075671A1 (en) * 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease
JP2010505883A (ja) * 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
EP2076129B1 (fr) 2006-10-12 2016-05-04 Research Foundation Of The City University Of New York Nouveaux curcumine dimère
US7871609B2 (en) * 2007-03-02 2011-01-18 Sam Ziff Supplements for pain management
BRPI0810899A2 (pt) * 2007-04-13 2014-10-29 Univ North Texas Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
WO2008144918A1 (fr) * 2007-05-29 2008-12-04 University Of Regina Procédé et composition absorbante pour récupérer un composant gazeux à partir d'un courant de gaz
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
JP5559067B2 (ja) * 2008-03-13 2014-07-23 シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイ ガスからの二酸化炭素の除去方法
US8062663B2 (en) * 2008-05-23 2011-11-22 National Health Research Instittues Methods and compostions for enhancing transdermal drug delivery
US20120003177A1 (en) * 2008-09-17 2012-01-05 Youqing Shen Curcumin-containing polymers and water-soluble curcumin derivatives as prodrugs of prodrug carriers
US8329757B2 (en) * 2008-10-14 2012-12-11 Charlesson, Llc Curcumin analog compositions and related methods
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070949A1 (fr) * 1999-05-20 2000-11-30 Heng Madalene C Y Methode d'utilisation de curcumin soluble pour inhiber une phosphorylase kinase dans des maladies inflammatoires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TONNESEN H H; KRISTENSEN S; GRINBERG L N: "Studies on curcumin and curcuminoids: XXV. Inhibition of primaquine-induced lysis of human red blood cells by curcumin", INTERNATIONAL JOURNAL OF PHARMACEUTICS - 1994, vol. 110, 1994 - 1994, pages 161, XP002692777 *

Also Published As

Publication number Publication date
US20140234402A1 (en) 2014-08-21
WO2011063178A3 (fr) 2011-09-22
US20110117186A1 (en) 2011-05-19
EP2501372A2 (fr) 2012-09-26
WO2011063178A2 (fr) 2011-05-26
US8747890B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
EP2501372A4 (fr) Infusion intraveineuse de curcumine et de bloqueur des canaux calciques
IL245262A (en) Catheter with curved end section
ZA201107811B (en) Iv catheter introducer
EP2407195A4 (fr) Joint et seringue
SG191090A1 (en) Subcutaneously infusible levodopa prodrug compositions and methods of infusion
EP2379424A4 (fr) Ensemble de perfusion
EP2384778A4 (fr) Dispositif de perfusion médicamenteuse
HK1177158A1 (en) Infusion site interfaces and insertion devices for infusion site interfaces
EP2651489A4 (fr) Dispositif d'introduction de cathéter comprenant une valve et un actionneur de valve
EP2450046A4 (fr) Composition à visée médicale pour le traitement de la bronchite et sa préparation
PT2389212T (pt) Seringa
EP2422832A4 (fr) Seringue pour injection de fil chirurgical
HUE056843T2 (hu) Gyógyszerek infúziója
HK1213207A1 (zh) 用於將流體皮下注射到病人體內的設備
EP2578250A4 (fr) Dispositif d'aiguille à demeure
HK1155679A1 (en) Syringe for injecting a surgical gas
EP2484312A4 (fr) Dispositif d'injection d'agent médical
HK1167592A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
EP2501380A4 (fr) Perfusion lente de sulcardine et de ses sels
GB0906195D0 (en) Needle and syringe
EP2405748A4 (fr) Administration d'ibuprofène par voie intraveineuse
IL220114A0 (en) Syringe flange protector
EG26793A (en) Medical Injector
EP2381973A4 (fr) Ensemble de perfusion à composé anesthésique
GB201009375D0 (en) Intravenous infusion device

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120612

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/30 20060101ALI20130228BHEP

Ipc: A61P 35/00 20060101ALI20130228BHEP

Ipc: A61K 9/127 20060101ALI20130228BHEP

Ipc: A61P 25/00 20060101ALI20130228BHEP

Ipc: A61P 27/02 20060101ALI20130228BHEP

Ipc: A61K 31/12 20060101AFI20130228BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130313

17Q First examination report despatched

Effective date: 20131205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160505